2',3'-dideoxy-ADP | 70764-36-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: 2',3'-dideoxy-ADP
• 英文别名: O^5'-trihydroxydiphosphoryl-2',3'-adenosine；2',3'-Dideoxyadenosine-5'-diphosphate；[(2S,5R)-5-(6-aminopurin-9-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
• CAS: 70764-36-2
• 化学式: C₁₀H₁₅N₅O₈P₂
• 分子量: 395.205
• InChiKey: QYFSANXOEHYVFG-NKWVEPMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  192
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use
  申请人：NeXstar Pharmaceuticals, Inc.

  公开号：EP0350287A2

  公开（公告）日：1990-01-10

  Compounds are disclosed for treating AIDS, herpes, and other viral infections by means of lipid derivatives of antiviral agents. The compounds consist of nucleoside analogues having antiviral activity which are linked, commonly through a phosphate group at the 5′ position of the pentose residue, to one of a selected group of lipids. The lipophilic nature of these compounds provide advantages over the use of the nucleoside analogue alone. It also makes it possible to incorporate them into the lamellar structure of liposomes, either alone or combined with similar molecules. In the form of liposomes, these antiviral agents are preferentially taken up by macrophages and monocytes, cells which have been found to harbor the target HIV virus. Additional site specificity may be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins. Effective nucleoside analogues are dideoxynucleosides, azidothymine (AZT), and acyclovir; lipid groups may be glycolipids, sphingolipids, phospholipids or fatty acids. The compounds persist, after intracellular hydrolysis, as phosphorylated or non-phosphorylated antiviral nucleosides. The compounds are effective in improving the efficacy of antiviral nucleoside analogues by prolonging the antiviral activity after the administration of the drug has ended, and in preventing retroviral replication in HIV infections which have become resistant to therapy with conventional forms of the antiretroviral agents.

  公开了通过抗病毒剂的脂质衍生物治疗艾滋病、疱疹和其他病毒感染的化合物。这些化合物由具有抗病毒活性的核苷类似物组成，核苷类似物通常通过戊糖残基 5′位上的磷酸基团与一组选定的脂质中的一种相连接。与单独使用核苷类似物相比，这些化合物的亲脂性更具优势。这也使得它们可以单独或与类似分子结合，加入脂质体的片层结构中。在脂质体的形式下，这些抗病毒药物会优先被巨噬细胞和单核细胞吸收，而这些细胞已被发现携带目标 HIV 病毒。在脂质体中加入配体，如与病毒蛋白结合的单克隆抗体或其他肽或蛋白质，还可增加作用点的特异性。有效的核苷类似物有双脱氧核苷、叠氮胸苷（AZT）和阿昔洛韦；脂质基团可以是糖脂、鞘磷脂、磷脂或脂肪酸。这些化合物在细胞内水解后，以磷酸化或非磷酸化的抗病毒核苷形式存在。这些化合物可在给药结束后延长抗病毒活性，从而有效改善抗病毒核苷类似物的疗效，并可在对传统形式的抗逆转录病毒药物治疗产生耐药性的艾滋病毒感染中防止逆转录病毒复制。
• Methods of treating viral infections using antiviral liponucleotides
  申请人：——

  公开号：US20010033862A1

  公开（公告）日：2001-10-25

  Compounds are disclosed for treating AIDS, herpes, and other viral infections by means of lipid derivatives of antiviral agents. The compounds consist of nucleoside analogues having antiviral activity which are linked, commonly through a phosphate group at the 5′ position of the pentose residue, to one of a selected group of lipids. The lipophilic nature of these compounds provide advantages over the use of the nucleoside analogue alone. It also makes it possible to incorporate them into the lamellar structure of liposomes, either alone or combined with similar molecules. In the form of liposomes, these antiviral agents are preferentially taken up by macrophages and monocytes, cells which have been found to harbor the target HIV virus. Additional site specificity may be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins. Effective nucleoside analogues are dideoxynucleosides, azidothymine (AZT), and acyclovir; lipid groups may be glycolipids, sphingolipids, phospholipids or fatty acids. The compounds persist, after intracellular hydrolysis, as phosphorylated or non-phosphorylated antiviral nucleosides. The compounds are effective in improving the efficacy of antiviral nucleoside analogues by prolonging the antiviral activity after the administration of the drug has ended, and in preventing retroviral replication in HIV infections which have become resistant to therapy with conventional forms of the antiretroviral agents.

  公开了通过抗病毒剂的脂质衍生物治疗艾滋病、疱疹和其他病毒感染的化合物。这些化合物由具有抗病毒活性的核苷类似物组成，核苷类似物通常通过戊糖残基 5′位上的磷酸基团与一组选定的脂质中的一种相连接。与单独使用核苷类似物相比，这些化合物的亲脂性更具优势。这也使得它们可以单独或与类似分子结合，加入脂质体的片层结构中。在脂质体的形式下，这些抗病毒药物会优先被巨噬细胞和单核细胞吸收，而这些细胞已被发现携带目标 HIV 病毒。在脂质体中加入配体，如与病毒蛋白结合的单克隆抗体或其他肽或蛋白质，还可增加作用点的特异性。有效的核苷类似物有双脱氧核苷、叠氮胸苷（AZT）和阿昔洛韦；脂质基团可以是糖脂、鞘磷脂、磷脂或脂肪酸。这些化合物在细胞内水解后，以磷酸化或非磷酸化的抗病毒核苷形式存在。这些化合物可在给药结束后延长抗病毒活性，从而有效改善抗病毒核苷类似物的疗效，并可在对传统形式的抗逆转录病毒药物治疗产生耐药性的艾滋病毒感染中防止逆转录病毒复制。
• ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B
  申请人：VICAL, INC.

  公开号：EP0594677A1

  公开（公告）日：1994-05-04
• EP0594677A4
  申请人：——

  公开号：EP0594677A4

  公开（公告）日：1997-09-17
• EP1240355A4
  申请人：——

  公开号：EP1240355A4

  公开（公告）日：2004-12-08